Back

Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor

Tiburcio, P. D. B.; Chen, K.; Xu, L.; Chen, K. S.

2024-12-17 cancer biology
10.1101/2024.06.11.598518 bioRxiv
Show abstract

Wilms tumor is the most common kidney cancer in children, and diffuse anaplastic Wilms tumor is the most chemoresistant histological subtype. Here, we explore how Wilms tumor cells evade the common chemotherapeutic drug actinomycin D, which inhibits ribosomal RNA biogenesis. Using ribosome profiling, protein arrays, and a genome-wide knockout screen, we describe how actinomycin D disrupts protein homeostasis and blocks cell cycle progression. We found that, when ribosomal capacity is limited by actinomycin D treatment, anaplastic Wilms tumor cells preferentially translate proteasome components and upregulate proteasome activity. Based on these findings, we tested whether the proteasome inhibitor bortezomib sensitizes cells to actinomycin D treatment. Indeed, we found that the combination induces apoptosis both in vitro and in vivo and prolongs survival in xenograft models. Lastly, we show that increased levels of proteasome components are associated with anaplastic histology and worse prognosis in Wilms tumor patients. In sum, maintaining protein homeostasis is critical for Wilms tumor proliferation, and it can be therapeutically disrupted by blocking protein synthesis or turnover.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 14%
12.6%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 2%
9.7%
Similar papers in this journal
3
Cancer Research
● 130 papers in training set
Top 0.4%
6.7%
Similar papers in this journal
4
Cancer Research Communications
● 51 papers in training set
Top 0.2%
4.0%
Similar papers in this journal
5
Cell Reports Medicine
○ 153 papers in training set
Top 0.7%
4.0%
6
Nature Cancer
○ 39 papers in training set
Top 0.4%
4.0%
Similar papers in this journal
7
eLife
● 5828 papers in training set
Top 35%
3.2%
8
JCI Insight
● 277 papers in training set
Top 2%
3.2%
9
Cancer Discovery
● 66 papers in training set
Top 0.8%
3.1%
50% of probability mass above
10
Cell Chemical Biology
○ 94 papers in training set
Top 0.4%
2.8%
11
Cancers
○ 213 papers in training set
Top 2%
2.4%
12
Clinical Cancer Research
● 64 papers in training set
Top 0.9%
2.4%
13
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 24%
2.1%
14
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.4%
2.1%
15
npj Precision Oncology
○ 53 papers in training set
Top 0.7%
2.1%
16
Cancer Cell
○ 42 papers in training set
Top 0.7%
1.9%
17
Neuro-Oncology
◐ 36 papers in training set
Top 0.4%
1.7%
18
Blood
● 74 papers in training set
Top 0.8%
1.7%
19
Scientific Reports
○ 3612 papers in training set
Top 55%
1.7%
20
Oncogene
○ 85 papers in training set
Top 1%
1.1%
21
Science Advances
● 1243 papers in training set
Top 25%
1.1%
22
Communications Biology
○ 993 papers in training set
Top 22%
1.1%
23
iScience
○ 1154 papers in training set
Top 27%
1.1%
24
EMBO Molecular Medicine
○ 95 papers in training set
Top 3%
0.8%
25
Gastroenterology
○ 42 papers in training set
Top 1%
0.8%
26
ACS Chemical Biology
● 167 papers in training set
Top 3%
0.8%
27
Science Translational Medicine
● 127 papers in training set
Top 4%
0.6%
28
Molecular Cancer Research
● 49 papers in training set
Top 2%
0.6%
29
NAR Cancer
◐ 37 papers in training set
Top 0.9%
0.6%
30
Cell Death & Disease
147 papers in training set
Top 4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.